Effects of a TAFI-Inhibitor Combined with a Suboptimal Dose of rtPA in a Murine Thromboembolic Model of Stroke

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cerebrovascular Diseases

• Publication date

  2014-11-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000366266PMID 25401979
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thrombolytics in Acute Ischaemic Stroke: Historical Perspective and Future Opportunities

  2013cited by this paper
• Fingolimod Reduces Hemorrhagic Transformation Associated With Delayed Tissue Plasminogen Activator Treatment in a Mouse Thromboembolic Model

  2013cited by this paper
• Combining antithrombotic and fibrinolytic agents: can it be done?

  2013cited by this paper
• Very Low Cerebral Blood Volume Predicts Parenchymal Hematoma in Acute Ischemic Stroke

  2013cited by this paper
• Spontaneous Reperfusion after In Situ Thromboembolic Stroke in Mice

  2012cited by this paper
• Symptomatic Intracranial Hemorrhage following Intravenous Thrombolysis for Acute Ischemic Stroke: A Critical Review of Case Definitions

  2012cited by this paper
• Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke.

  2012cited by this paper
• A Mouse Model of Hemorrhagic Transformation by Delayed Tissue Plasminogen Activator Administration After In Situ Thromboembolic Stroke

  2011cited by this paper
• Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model.

  2011cited by this paper
• What has been learnt from the thrombin‐activatable fibrinolysis inhibitor‐deficient mouse?

  2010cited by this paper
• Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Deficient Mice Are Susceptible to Intracerebral Thrombosis and Ischemic Stroke

  2010cited by this paper
• Routine Use of Intravenous Low-Dose Recombinant Tissue Plasminogen Activator in Japanese Patients: General Outcomes and Prognostic Factors From the SAMURAI Register

  2009cited by this paper
• Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations

  2009cited by this paper
• Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses

  2009cited by this paper
• RODENT STROKE MODEL GUIDELINES FOR PRECLINICAL STROKE TRIALS (1ST EDITION).

  2009cited by this paper
• Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

  2008cited by this paper
• Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update

  2008cited by this paper
• Mouse Model of In Situ Thromboembolic Stroke and Reperfusion

  2007cited by this paper
• Influence of thrombin‐activatable fibrinolysis inhibitor and plasminogen activator inhibitor‐1 gene polymorphisms on tissue‐type plasminogen activator‐induced recanalization in ischemic stroke patients

  2007cited by this paper
• Determination of blood longitudinal relaxation time (T1) at high magnetic field strengths.

  2007cited by this paper
• Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats?

  2007cited by this paper
• G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences

  2007cited by this paper
• A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) – Part II: Enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis

  2006cited by this paper
• Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study

  2006cited by this paper
• Rodent models of focal stroke: Size, mechanism, and purpose

  2005cited by this paper
• An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.

  2000cited by this paper
• Recommendations for standards regarding preclinical neuroprotective and restorative drug development.

  1999cited by this paper
• Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

  1998cited by this paper
• Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.

  1995cited by this paper
• Tissue plasminogen activator for acute ischemic stroke.

  1995cited by this paper
• Factors Related to Intracranial Hematoma Formation in Patients Receiving Tissue‐Type Plasminogen Activator forAcute Ischemic Stroke

  1994cited by this paper

• Reduced Folate Carrier 1 (RFC1/Slc19a1) Suppression Exacerbates Blood-Brain Barrier Breakdown in Experimental Ischemic Stroke in Adult Mice

  2024cites this paper
• Brain Expression of CPB2 and Effects of Cpb2 Deficiency in Mouse Models of Behavior

  2023cites this paper
• Composition and Organization of Acute Ischemic Stroke Thrombus: A Wealth of Information for Future Thrombolytic Strategies

  2022cites this paper
• Thrombolytic strategies for ischemic stroke in the thrombectomy era

  2021cites this paper
• Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?

  2021cites this paper
• Selective inhibition of carboxypeptidase U may reduce microvascular thrombosis in rat experimental stroke

  2020cites this paper
• Neurologic Complications of Infective Endocarditis: A Joint Model for a Septic Thromboembolism and Inflammatory Small Vessel Disease.

  2019cites this paper
• 1. Changing demographics of stroke and impact on thrombolysis and thrombectomy

  2019cites this paper
• Combining Intravenous Thrombolysis and Antithrombotic Agents in Stroke: An Update

  2018cites this paper
• Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin‐activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different in vitro models

  2018cites this paper
• Animal Models of Focal Cerebral Ischaemia and Haemorrhagic Transformation: Considerations in Experimental Stroke Study Design.

  2018cites this paper
• Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome

  2016cites this paper
• Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke: A Retrospective Pooled Analysis

  2016cites this paper
• Lack of TAFI increases brain damage and microparticle generation after thrombolytic therapy in ischemic stroke.

  2015cites this paper
• [Intravenous thrombolysis in ischemic stroke: Therapeutic perspectives].

  2015cites this paper